Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TransCon PTH Impact on Brain Function and Quality of Life in Hypoparathyroidism
2025-523930-14-00Phase 4Authorised
- Sponsor
- Central Denmark Region
- Start
- Apr 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of palopegteriparatide in hypoparathyroidism (2 arms), sponsored by Central Denmark Region. Planned start Apr 2026; status: authorised.
02
Drugs
palopegteriparatide
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on 2025-523930-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523930-14-00.